Drug Profile
Research programme: G protein-coupled receptor antagonists - Novasite Pharmaceuticals
Latest Information Update: 30 Mar 2009
Price :
$50
*
At a glance
- Originator Novasite Pharmaceuticals
- Class
- Mechanism of Action G protein-coupled receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Autoimmune disorders; Cancer; Obesity; Pain; Psychotic disorders
Most Recent Events
- 09 Dec 2004 Novasite and The Stanley Medical Research Institute formed an alliance to develop allosteric GPCR modulators
- 22 Sep 2003 Preclinical trials in Autoimmune disorders in USA (unspecified route)
- 22 Sep 2003 Preclinical trials in Cancer in USA (unspecified route)